Today is 2019-07-21

Serum gamma-glutamyltransferase, Ferritin, uric acid and their interaction on the risk of type 2 diabetes
download

注册号:

Registration number:

ChiCTR-OCS-09000361 

最近更新日期:

Date of Last Refreshed on:

2015-05-10 

注册时间:

Date of Registration:

2009-03-20 

注册号状态:

补注册  

Registration Status:

Retrospective registration  

注册题目:

 

Public title:

Serum gamma-glutamyltransferase, Ferritin, uric acid and their interaction on the risk of type 2 diabetes 

注册题目简写:

 

English Acronym:

 

研究课题的正式科学名称:

 

Scientific title:

Serum gamma-glutamyltransferase, Ferritin, uric acid and their interaction on the risk of type 2 diabetes 

研究课题代号(代码):

Study subject ID:

 

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

 

申请注册联系人:

 

研究负责人:

 

Applicant:

Tao Chen or Haoming Tian 

Study leader:

Haoming Tian 

申请注册联系人电话:

Applicant telephone:

+86 028 81812303 

研究负责人电话:

Study leader's telephone:

+86 028 81812303 

申请注册联系人传真 :

Applicant Fax:

+86 028 85422357 

研究负责人传真:

Study leader's fax:

+86 028 85422357 

申请注册联系人电子邮件:

Applicant E-mail:

dr.chentao@gmail.com 

研究负责人电子邮件:

Study leader's E-mail:

tianhaoming2006@yahoo.com 

申请单位网址(自愿提供):

Applicant website(voluntary supply):

 

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

 

申请注册联系人通讯地址:

 

研究负责人通讯地址:

 

Applicant address:

Department of Endocrinology, West China Hospital, Sichuan University 

Study leader's address:

Department of Endocrinology, West China Hospital, Sichuan University 

申请注册联系人邮政编码:

Applicant postcode:

610041 

研究负责人邮政编码:

Study leader's postcode:

610041 

申请人所在单位:

 

Applicant's institution:

Tao Chen (Department of Endocrinology and Metabolism, West China hospital, Sichuan University) 

是否获伦理委员会批准:

是 

Approved by ethic committee:

Yes 

伦理委员会批件文号:

Approved No. of ethic committee:

07020470055 

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

 

Name of the ethic committee:

China-Japan Friendship Hospital's Drugs / Medical Apparatus & Instruments Ethics Committee 

伦理委员会批准日期:

Date of approved by ethic committee:

2008-09-05 

伦理委员会联系人:

 

Contact Name of the ethic committee:

 

伦理委员会联系地址:

 

Contact Address of the ethic committee:

 

伦理委员会联系人电话:

Contact phone of the ethic committee:

 

伦理委员会联系人邮箱:

Contact email of the ethic committee:

 

研究实施负责(组长)单位:

 

Primary sponsor:

Laboratory of Endocrine and Metabolism of West China Hospital, Sichuan University 

研究实施负责(组长)单位地址:

 

Primary sponsor's address:

No.37, Guoxue Lane, Chengdu City, Sichuan Province, China 

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

 

Source(s) of funding:

Post graduate student Funding 

研究疾病:

 

Target disease:

Type 2 diabetes 

研究疾病代码:

 

Target disease code:

 

研究类型:

观察性研究 

Study type:

Observational study 

研究所处阶段:

I期临床试验 

Study phase:

研究目的:

 

Objectives of Study:

The present study was to investigate the relationship of GGT, Ferrtin and UA and to investigate their interaction on the risk of type 2 diabetes 

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

研究设计:

横断面 

Study design:

Cross-sectional 

纳入标准:

 

Inclusion criteria

type 2 diabetic patients and controls are defined according to according to WHO recommendation (1999) 

排除标准:

 

Exclusion criteria:

1. patients with Type 1 diabetes mellitus and Other specific types of diabetes; 2. patients with severe diseases in heart, liver and kidney. 

研究实施时间:

Study execute time:

From2007-01-01To 2010-03-31 

干预措施:

Interventions:

组别:

样本量:

550

Group:

Subjects from countryside

Sample size:

干预措施:

干预措施代码:

Intervention:

Plasma glucose; GGT; Ferritin; UA; MDA

Intervention code:

组别:

样本量:

55

Group:

Subjects from town

Sample size:

干预措施:

干预措施代码:

Intervention:

Plasma glucose; GGT; Ferritin; UA; MDA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

 

省(直辖市):

 

市(区县):

 

Country:

China 

Province:

Sichuan 

City:

Chengdu 

单位(医院):

 

单位级别:

 

Institution
hospital:

West China hospital  

Level of the institution:

Tertiary A hospital 

测量指标:

Outcomes:

指标中文名:

指标类型:

主要指标 

Outcome:

The risk of type 2 diabete

Type:

Primary indicator 

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

指标类型:

次要指标 

Outcome:

MDA

Type:

Secondary indicator 

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

结束

Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 74 years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

Convenience Selection

盲法:

Blinding:

none

试验完成后的统计结果(上传文件):

Calculated Results ater
the Study Completed(upload file):

原始数据公开时间:

The time of sharing IPD:

Real time access

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Department of Endocrinology, West China Hospital, Sichuan University

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Department of Endocrinology, and Department of Statistics, Sichuan University

数据管理委员会:

Data Managemen Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2009-03-20
return list